A review of new insights into existing major depressive disorder biomarkers

As major depressive disorder (MDD) is such a diverse condition, there are currently no clear ways for determining its severity, endophenotype, or therapy response. The distinctive nature of depression, the variability of analysis in literature and the large number of conceptually complicated biomark...

Full description

Bibliographic Details
Main Authors: Fahmida Hoque Rimti, Reemal Shahbaz, Kunj Bhatt, Alex Xiang
Format: Article
Language:English
Published: Elsevier 2023-08-01
Series:Heliyon
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2405844023061170
_version_ 1797732949114748928
author Fahmida Hoque Rimti
Reemal Shahbaz
Kunj Bhatt
Alex Xiang
author_facet Fahmida Hoque Rimti
Reemal Shahbaz
Kunj Bhatt
Alex Xiang
author_sort Fahmida Hoque Rimti
collection DOAJ
description As major depressive disorder (MDD) is such a diverse condition, there are currently no clear ways for determining its severity, endophenotype, or therapy response. The distinctive nature of depression, the variability of analysis in literature and the large number of conceptually complicated biomarkers are some of the many reasons for the lack of progress. Markers are involved in the process of neurotrophic, metabolic, and inflammation as well as neuroendocrine and neurotransmitter systems’ components. Some clinical indicators are strong enough so that can be measured using assessments of proteomic, genetic, metabolomics, neuroimaging, epigenetic and transcriptomic. Markers of oxidative stress, endocrine, inflammatory, proteomic, and growth indicators are currently among the promising biologic systems/markers identified in this analysis. This narrative review examines succinct studies which investigated cytokines of inflammatory factors, peripheral factors of development, metabolic and endocrine markers as pathophysiological biomarkers of MDD, and treatment responses. Endocrine and metabolic alterations have also been linked to MDD in various studies. So, this study summarizes all of the numerous biomarkers that are significant in the detection or treatment of MDD patients. The paper also provides an overview of various biomarkers which are important for the regulation and its effects on MDD.
first_indexed 2024-03-12T12:21:52Z
format Article
id doaj.art-a86cbf442326418189114dd0c82d2d9c
institution Directory Open Access Journal
issn 2405-8440
language English
last_indexed 2024-03-12T12:21:52Z
publishDate 2023-08-01
publisher Elsevier
record_format Article
series Heliyon
spelling doaj.art-a86cbf442326418189114dd0c82d2d9c2023-08-30T05:53:04ZengElsevierHeliyon2405-84402023-08-0198e18909A review of new insights into existing major depressive disorder biomarkersFahmida Hoque Rimti0Reemal Shahbaz1Kunj Bhatt2Alex Xiang3Chittagong Medical College, Chittagong, 4203, Bangladesh; Corresponding author.McMaster University, Ontario, 00000, CanadaMcMaster University, Ontario, 00000, CanadaMcMaster University, Ontario, 00000, CanadaAs major depressive disorder (MDD) is such a diverse condition, there are currently no clear ways for determining its severity, endophenotype, or therapy response. The distinctive nature of depression, the variability of analysis in literature and the large number of conceptually complicated biomarkers are some of the many reasons for the lack of progress. Markers are involved in the process of neurotrophic, metabolic, and inflammation as well as neuroendocrine and neurotransmitter systems’ components. Some clinical indicators are strong enough so that can be measured using assessments of proteomic, genetic, metabolomics, neuroimaging, epigenetic and transcriptomic. Markers of oxidative stress, endocrine, inflammatory, proteomic, and growth indicators are currently among the promising biologic systems/markers identified in this analysis. This narrative review examines succinct studies which investigated cytokines of inflammatory factors, peripheral factors of development, metabolic and endocrine markers as pathophysiological biomarkers of MDD, and treatment responses. Endocrine and metabolic alterations have also been linked to MDD in various studies. So, this study summarizes all of the numerous biomarkers that are significant in the detection or treatment of MDD patients. The paper also provides an overview of various biomarkers which are important for the regulation and its effects on MDD.http://www.sciencedirect.com/science/article/pii/S2405844023061170Major depressive disorderInsulin-like growth factor IBrain-derived neurotrophic factorMood disordersIL-1b
spellingShingle Fahmida Hoque Rimti
Reemal Shahbaz
Kunj Bhatt
Alex Xiang
A review of new insights into existing major depressive disorder biomarkers
Heliyon
Major depressive disorder
Insulin-like growth factor I
Brain-derived neurotrophic factor
Mood disorders
IL-1b
title A review of new insights into existing major depressive disorder biomarkers
title_full A review of new insights into existing major depressive disorder biomarkers
title_fullStr A review of new insights into existing major depressive disorder biomarkers
title_full_unstemmed A review of new insights into existing major depressive disorder biomarkers
title_short A review of new insights into existing major depressive disorder biomarkers
title_sort review of new insights into existing major depressive disorder biomarkers
topic Major depressive disorder
Insulin-like growth factor I
Brain-derived neurotrophic factor
Mood disorders
IL-1b
url http://www.sciencedirect.com/science/article/pii/S2405844023061170
work_keys_str_mv AT fahmidahoquerimti areviewofnewinsightsintoexistingmajordepressivedisorderbiomarkers
AT reemalshahbaz areviewofnewinsightsintoexistingmajordepressivedisorderbiomarkers
AT kunjbhatt areviewofnewinsightsintoexistingmajordepressivedisorderbiomarkers
AT alexxiang areviewofnewinsightsintoexistingmajordepressivedisorderbiomarkers
AT fahmidahoquerimti reviewofnewinsightsintoexistingmajordepressivedisorderbiomarkers
AT reemalshahbaz reviewofnewinsightsintoexistingmajordepressivedisorderbiomarkers
AT kunjbhatt reviewofnewinsightsintoexistingmajordepressivedisorderbiomarkers
AT alexxiang reviewofnewinsightsintoexistingmajordepressivedisorderbiomarkers